Human antiglobulin response to foreign antibodies: Therapeutic benefit?

Cancer Immunology, Immunotherapy

Volumn 52, Issue 5, 2003, Pages 309-316

  DeNardo, Gerald L ^a   Bradt, Bonnie M ^a   Mirick, Gary R ^a   DeNardo, Sally J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antibody; Cancer; Human anti mouse antibody; Immunotherapy; Radioimmunotherapy

Indexed keywords

IBRITUMOMAB TIUXETAN; IMMUNOGLOBULIN ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY LYM 1; RITUXIMAB; TOSITUMOMAB I 131;

ANAPHYLAXIS; ANTIBODY RESPONSE; ANTIBODY TITER; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; HOT FLUSH; HUMAN; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RASH; SERUM SICKNESS; SIDE EFFECT;

EID: 0038054750     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-002-0350-y     Document Type: Conference Paper

References (74)

1. Adams GP, DeNardo SJ, Amin A, Kroger LA, DeNardo GL, Hellstrom I, Hellstrom KE (1992) Comparison of the pharmacokinetics in mice and the biological activity of murine L6 and human-mouse chimeric Ch-L6 antibody. Antibody Immunoconj Radiopharm 5:81
2. Baum RP, Neisen A, Hertel A, Hess H, Donnerstag B, Sykes T, Sykes C, Suresh M, Noujaim A, Hor G (1994) Activating anti-idiotypic human anti-mouse antibodies for immunotherapy of ovarian carcinoma. Cancer 1:73 (3):1121
3. Bhattacharya-Chatterjee M, Chatterjee SK, Foon KA (2000) Anti-idiotype vaccine against cancer. Immunol Lett 74:51
4. Carrasquillo JA, Mulshine JL, Bunn PA (1987) Indium-111 T101 monoclonal antibodies are superior to iodine-131 T101 in imaging cutaneous T-cell lymphoma. J Nucl Med 28:281
5. Chester KA, Begent RH, Robson L, Keep P, Pedley RB, Boden JA, Boxer G, Green A, Winter G, Cochet O (1994) Phage libraries for generation of clinically useful antibodies. Lancet 343:455
6. Cheung NK, Guo HF, Cheung IY (2000) Correlation of anti-idiotype network with survival following anti-G(D2) monoclonal antibody 3F8 therapy of stage 4 neuroblastoma. Med Pediatr Oncol 35:635
7. Cheung NK, Guo HF, Heller G, Cheung IY (2000) Induction of Ab3 and Ab3' antibody associated with long-term survival after anti-G(D2) antibody therapy of stage 4 neuroblastoma. Clin Cancer Res 6:2653
8. Courtenay-Luck NS, Epenetos AA, Moore R, Larche M, Pectasides D, Dhokia B, Ritter MA (1986) Development of primary and secondary immune responses to mouse monoclonal antibodies used in the diagnosis and therapy of malignant neoplasm. Cancer Res 46:6489
9. Courtenay-Luck NS, Epenetos AA, Sivolapenko GB, Larche M, Barkans JR, Ritter MA (1988) Development of anti-idiotypic antibodies against tumour antigens and autoantigens in ovarian cancer patients treated intraperitoneally with mouse monoclonal antibodies. Lancet 2:894
10. 131I-Lym-1 antibody. Cancer Biother Radiopharm 13:239
11. 131I-Lym-1. Int J Biol Markers 10:67
12. 131I-Lym-1 mAb for B-cell malignancies. J Nucl Med 43:312
13. DeNardo GL, O'Donnell RT, Rose LM, Mirick GR, Kroger LA, DeNardo SJ (1999) Milestones in the development of Lym-1 therapy. Hybridoma 18:1
14. DeNardo SJ, DeNardo GL, DeNardo DG, Xiong CY, Shi XB, Winthrop MD, Kroger LA, Carter P (1999) Antibody phage libraries for the next generation of tumor targeting radioimmunotherapeutics. Clin Cancer Res 10:3213
15. DeNardo SJ, Kroger LA, MacKenzie MR, Mirick GR, Shen S, DeNardo GL (1998) Prolonged survival associated with immune response in a patient treated with Lym-1 mouse monoclonal antibody. Cancer Biother Radiopharm 13:1
16. DeNardo SJ, O'Grady LF, Macey DJ, Kroger LA, DeNardo GL, Lamborn KR, Levy NB, Mills SL, Hellstrom I, Hellstrom KE (1991) Quantitative imaging of mouse L-6 monoclonal antibody in breast cancer patients to develop a therapeutic strategy. Int J Rad Appl Instrum B 18:621
17. Dhingra K, Fritsche H, Murray JL, LoBuglio AF, Khazaeli MB, Kelley S, Tepper M, Greene D, Booser D, Buzdar A, Raber M, Gutierrez L, Hortobagyi G (2002) Suppression of human anti-mouse antibody response to murine monoclonal antibody L6 by deoxyspergualin: a phase I study. In: Ceriani RL (ed) Breast cancer research and immunology. Plenum Publishing Press, New York
18. Dillman RO, Shawler DL, Dillman JB, Royston I (1984) Therapy of chronic lymphocytic leukemia and cutaneous T-cell lymphoma with T101 monoclonal antibody. J Clin Oncol 2:881
19. Fagerberg J, Hjelm AL, Ragnhammar P, Frodin JE, Wigzell H, Mellstedt H (1995) Tumor regression in monoclonal antibody-treated patients correlates with the presence of anti-idiotype-reactive T lymphocytes. Cancer Res 55:1824
20. Fagnani K, Hagan MS, Bartholomew R (1990) Reduction of immunogenicity by covalent modification of murine and rabbit immunoglobulins with oxidize dextrans of low molecular weight. Cancer Res 50:3638
21. Ferrone S (1993) Human tumor-associated antigen mimicry by anti-idiotypic antibodies. Immunogenicity and clinical trials in patients with solid tumors. Ann NY Acad Sci 690:214
22. Foon KA, Chakraborty M, John WJ, Sherratt A, Kohler H, Bhattacharya-Chatterjee M (1995) Immune response to the carcinoembryonic antigen in patients treated with an anti-idiotype antibody vaccine. J Clin Invest 96:334
23. Frodin JE, Faxas ME, Hagstrom B, Lefvert AK, Masucci G, Nilsson B, Steinitz M, Unger P, Mellstedt H (1991) Induction of anti-idiotypic (ab2) and anti-anti-idiotypic (ab3) antibodies in patients treated with mouse monoclonal antibody 17-1A (ab1). Relation to the clinical outcome - an important antitumoral effector function? Hybridoma 10:421
24. Frodin JE, Lefvert AK, Mellstedt H (1992) The clinical significance of HAMA in patients treated with mouse monoclonal antibodies. Cell Biophys 21:153
25. Gruber R, van Haarlem LJM, Warnaar SO, Holz E, Riethmuller G (2000) The human antimouse immunoglobulin response and the anti-idiotypic network have no influence on clinical outcome in patients with minimal residual colorectal cancer treated with monoclonal antibody CO17-1A. Cancer Res 60:1921
26. Gupta S (1981) Immunodeficiencies in Hodgkin's disease. Part I: T-cell mediated immunity, Part II: B cell immunity, complement systems and phagocytic cell systems. Clin Bull 11:58
27. Herlyn D, Ross AH, Koprowski H (1986) Anti-idiotypic antibodies bear the internal image of a human tumor antigen. Science 232:100
28. Herlyn D, Somasundaram R, Li W, Maruyama H (1996) Review: anti-idiotype cancer vaccines: past and future. Cancer Immunol Immunother 43:65
29. Herlyn D, Wettendorff M, Schmoll E, Iliopoulos D, Schedel I, Dreikhausen U, Raab R, Ross AH, Jaksche H, Scriba M, Koprowski H (1987) Anti-idiotype immunization of cancer patients: modulation of the immune response. Proc Natl Acad Sci USA 84:8055
30. Herlyn D, Zaloudik J, Somasundaram R, Jacob L, Benden A, Mastangelo M (1993) Anti-idiotype vaccine in colorectal cancer patients. Hybridoma 12:515
31. Houghton AN, Mintzer D, Cordon-Cardo C, Welt S, Fliegel B, Vadhan S, Carswell E, Melamed MR, Oettgen HF, Old LJ (1985) Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma. Proc Natl Acad Sci USA 82:1242
32. Jerne NK (1974) Towards a network theory of the immune system. Ann Immunol (Paris) 125C:373
33. Juweid M, Sharkey RM, Markowitz A, Behr TM, Swayne LC, Dunn R, Hansen HJ, Shevitz J, Leung SO, Rubin AD, Herskovic T, Hanley D, Goldenberg DM (1995) Treatment of non-Hodgkin's lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22 monoclonal antibody. Cancer Res 55:5899s
34. Kaminiski MS, Estes J, Zasadny KR, Francis IR, Ross CW, Tuck M, Regan D, Fisher S, Gutierrez J, Kroll S, Stagg R, Tidmarsh G, Wahl RL (2000) Radioimmunotherapy with iodine (131)I tositumomab for relapsed refractory B-cell non-Hodgkin lymphoma: update results and long-term follow-up of the University of Michigan experience. Blood 96:1259
35. Kaminski M, Zasadny K, Francis L, Fenner M, Ross C, Milik A, Estes J, Tuck M, Regan D, Fisher S, Glenn S, Wald R (1996) Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol 14:1974
36. Kaminski MS, Estes J, Zasadny KR, Francis IR, Ross CW, Tuck M, Regan D, Fisher S, Gutierrez J, Kroll S, Stagg R, Tidmarsh G, Wahl RL (2000) Radioimmunotherapy with iodine (131)I tositumomab for relapsed refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 96:1259
37. Khazaeli MB, Conry M, LoBuglio AF (1994) Human immune response to monoclonal antibodies. J Immunother 15:42
38. 131I-chimeric mouse/human B72.3 (human gamma 4) monoclonal antibody in humans. Cancer Res 51:5461
39. Kimura K, Takahashi T, Yamaguchi T, Noguchi A, Takashina K, Tsurumi H, Inagake M, Toyokuni T, Hakomori S (1991) Chemical engineering of the monoclonal antibody A7 by polyethylene glycol for targeting cancer chemotherapy. Cancer Res 51:4310
40. Knox SJ, Goris ML, Trisler K, Negrin R, Davis T, Liles T-M, Grillo-Lopez AJ, Chinn P, Varns C, Ning S-C, Fowler S, Deb N, Becker M, Marquez C, Levy R (1996) Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res 2:457
41. Koprowski H, Herlyn D, Lubeck M, DeFreitas E, Sears H (1984) Human anti-idiotype in cancer patients: is the modulation of the immune response beneficial for the patient. Proc Natl Acad Sci USA 81:216
42. Kosmas C, Epenetos AA, Courtenay-Luck NS (1994) Activation of cellular immunity after intracavitary monoclonal antibody therapy of ovarian cancer. Cancer 73:3000
43. Kosmas C, Epenetos AA, Courtney-Luck NS (1991) Patients receiving murine monoclonal antibody therapy for malignancy develop T cells that proliferate in vitro in response to these antibodies as antigens. Br J Cancer 64:494
44. Kosmas C, Snook D, Gooden CS, Courtenay-Luck NS, McCall MJ, Meares CF, Epenetos AA (1992) Development of humoral immune responses against a macrocyclic chelating agent (DOTA) in cancer patients receiving radioimmunoconjugates for imaging and therapy. Cancer Res 52:904
45. Kuus-Reichel K, Grauer LS, Karavodin LM, Knott C, Krusemeier M, Kay NE (1994) Will immunogenicity limit the use, efficacy, and future development of therapeutic monoclonal antibodies? Clin Diagn Lab Immunol 1:365
46. Lamborn KR, DeNardo GL, DeNardo SJ, Goldstein DS, Shen S, Larkin EC, Kroger LA (1997) Treatment-related parameters predicting efficacy of Lym-1 radioimmunotherapy in patients with B-lymphocytic malignancies. Clin Cancer Res 3:1253
47. Lanzavecchia A, Abrignani S, Scheidegger D, Obrist R, Dorken B, Moldenhauer G (1988) Antibodies as antigens. The use of mouse monoclonal antibodies to focus human T cells against selected targets. J Exp Med 167:345
48. Ledermann JA, Begent RH, Bagshawe KD, Riggs SJ, Searle F, Glaser MG, Green AJ, Dale RG (1988) Repeated antitumour antibody therpay in man with suppression of the host response by cyclosporin A. Br J Cancer 58:654
49. Liu SY, Eary JF, Petersdorf SH, Martin PJ, Maloney DG, Appelbaum FR, Matthews DC, Bush SA, Durack LD, Fisher DR, Gooley TA, Bernstein ID, Press OW (1998) Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue. J Clin Oncol 16:3270
50. LoBuglio AF, Khazaeli MB, Lee J, Haynes A, Sumerel L, Mischak R, Spitler L (1988) Pharmacokinetics and immune response to Xomazyme-Mel in melanoma patients. Antibody Immunoconj Radiopharm 1:305
51. LoBuglio AF, Saleh MN, Lee J, Khazaeli MB, Carrano R, Holden H, Wheeler RH (1988) Phase I trial of multiple large doses of murine monoclonal antibody CO17-1A. I. Clinical aspects. J Natl Cancer Inst 80:932
52. Madiyalakan R, Sykes TR, Dharampaul S, Sykes CJ, Baum RP, Hor G, Noujaim AA (1995) Antiidiotype induction therapy: evidence for the induction of immune response through the idiotype network in patients with ovarian cancer after administration of anti-CA125 murine monoclonal antibody B43.13. Hybridoma 14:199
53. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825
54. Meeker TC, Lowder J, Maloney DG, Miller RA, Thielemans K, Warnke R, Levy R (1985) A clinical trial of anti-idiotype therapy for B cell malignancy. Blood 65:1349
55. Meredith RF, Khazaeli MB, Plott WE, Liu T, Russell CD, Wheeler RH, LoBuglio AF (1993) Effect of human immune-response on repeat courses of I-131 chimeric B72.3 antibody therapy. Antibody Immunoconj Radiopharm 6:39
56. Miotti S, Negri DR, Valota O, Calabrese M, Bolhuis RL, Gratama JW, Colnaghi MI, Canevari S (1999) Level of anti-mouse-antibody response induced by bi-specific monoclonal antibody OC/TR in ovarian-carcinoma patients is associated with longer survival. Int J Cancer 84:62
57. Mittelman A, Chen ZJ, Yang H, Wong GY, Ferrone S (1992) Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma. Proc Natl Acad Sci USA 89:466
58. Mittelman A, Wang X, Matsumoto K, Ferrone S (1995) Antiantiidiotypic response and clinical course of the disease in patients with malignant melanoma immunized with mouse antiidiotypic monoclonal antibody MK2-23. Hybridoma 14:175
59. Morrison SL (1985) Transfectomas provide novel chimeric antibodies. Science 229:1202
60. Oehr P, Wagner U, Briele B, Hotze A, Schmidt S, Reinsberg J, Liu Q, Ota Y, Krebs D, Biersack HJ (1991) Improved survival of patients with advanced ovarian carcinoma after repeated immunoscintigraphy and induction of anti-idiotypic antibodies [abstract]. Eur J Nucl Med 18:529
61. Oratz R, Speyer JL, Wernz JC, et al (1990) Antimelanoma monoclonal antibody-ricin A chain immunoconjugate (XMME-001-RTA) plus cyclophosphamide in treatment of metastatic malignant melanoma: results of a phase II trial. J Biol Response Modif 9:345
62. Reff ME, Heard C (2001) A review of modifications to recombinant antibodies: attempt to increase efficacy in oncology applications. Crit Rev Oncol Hematol 40:25
63. Riechmann L, Clark M, Waldmann H, Winter G (1988) Reshaping human antibodies for therapy. Nature 332:323
64. Riethmuller G, Schneider-Gadicke E, Schlimok G, Schmiegel W, Raab R, Hoffken K, Gruber R, Pichlmaier H, Hirche H, Pichlmayr R (1994) Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study Group [see comments]. Lancet 343:1177
65. 131I-labeled monoclonal antibody: an Illinois Cancer Council study. J Clin Oncol 5:562
66. Schroff RW, Foon KA, Beatty SM, Oldham RK, Morgan AC Jr (1985) Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy. Cancer Res 45:879
67. Sears H, Herlyn D, Koprowski H, Shen J (1984): Immunotherapy of gastrointestinal malignancies with a murine IgG2A antibody. In: Riethmuller G, Koprowski H, von Kleist S, Munk K (eds) Genes and antigens in cancer cells. Karger, Basel, pp 180
68. Sears HF, Atkinson B, Mattis J, Ernst C, Herlyn D, Steplewski Z, Hayry P, Koprowski H (1982) Phase I clinical trial of monoclonal antibody in treatment of gastrointestinal tumors. Lancet 762
69. Shawler DL, Bartholomew RM, Smith LM, Dillman RO (1985) Human immune response to multiple injections of murine monoclonal IgG1. J Immunol 135:1530
70. Torres G, Berna L, Estorch M, Juarez C, Martinez-Duncker D, Carrio I (1993) Preexisting human anti-murine antibodies and the effect of immune complexes on the outcome of immunoscintigraphy. Clin Nucl Med 18:477
71. Wagner U, Reinsberg J, Oehr P, Briele B, Schmidt S, Werner A, Krebs D, Biersack HJ (1990) Clinical course of patients with ovarian carcinomas after the induction of anti-idiotypic antibodies against a tumor associated antigen. An approach to immunotherapy of advanced ovarian cancer. Tumor Diagn Ther 11:1
72. Wagner UA, Oehr PF, Reinsberg J, Schmidt SC, Schlehbusch HW, Schultes B, Werner A, Prietl G, Krebs D (1992) Immunotherapy of advanced ovarian carcinomas by activation of the idiotypic network. Biotechnol Ther 3:81
73. Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, Pohlman BL, Bartlett NL, Wiseman GA, Padre N, Grillo-Lopez AJ, Multani P, White CA (2002) Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 20:2453
74. Zimmer AM, Rosen ST, Spies SM, Goldman-Leikin R, Kazikiewicz JM, Silverstein EA, Kaplan EH (1988) Radioimmunotherapy of patients with cutaneous T-cell lymphoma using an iodine-131-labeled monoclonal antibody: analysis of retreatment following plasmapheresis. J Nucl Med 29:174